Criteria Bio Ventures
Venture capitalBarcelona · Seed–Late Stage · 7 people tracked
Find your way into Criteria Bio Ventures
1,437 people in our graph share verified history with the Criteria Bio Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Criteria Bio Ventures partners long-term with entrepreneurs and co-investors developing disruptive, well-protected innovations in healthcare that address significant unmet medical needs. The fund invests in private biotech companies across Europe and North America, with a special focus on Spain and Portugal. It takes a modality- and disease-agnostic approach, backing therapies across a wide range of areas, and offers evergreen support until meaningful impact is achieved. The firm frequently acts as a cornerstone or early investor, helping companies advance from academia to the clinic and secure larger financing syndicates for later clinical phases.
Source: firm website, verified Aug 3, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 15 of 22 portfolio companiesBiotech ×12Healthtech ×10Medical Devices ×5Deep Tech ×3Digital Health ×3Longevity ×3Wellness & Fitness ×2AgTech ×1
HQs:Spain×7United States×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×42 founders×43 founders×1
Investments · 22 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 13 dated
AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)inCarole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsNewton BiocapitalSound BioventuresSambrinvestWallonie Entreprendre
Adaptam Therapeutics develops antibody-based cancer immunotherapies, including antibody-drug conjugates and bispecific antibodies, that target the immunosuppressive myeloid tumor microenvironment via novel targets such as glycan-binding proteins and Siglecs.
BiotechHealthtechSan Sebastián, ES
Asis Palazon(CEO/CSO & Founder)in
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsNovartis Venture FundSV Health InvestorsBritish Business BankM VenturesDementia Discovery Fund
AELIX Therapeutics is a company developing a therapeutic HIV vaccine intended for use in HIV cure and eradication strategies.
BiotechHealthtechBarcelona, ES
Co-investorsYsios Capital
aptaTargets develops aptamer-based therapeutics and diagnostics for cerebrovascular diseases, with a lead program (ApTOLL) targeting stroke treatment.
AI & Machine LearningBiotechHealthtechMedical DevicesMadrid, ES
David(Co-Founder & CEO)Maria Eugenia(Co-Founder & CFO)in
Co-investorsInveready Technology Investment Group
Circe Scientific provides DMPK (drug metabolism and pharmacokinetics) and PK/PD consulting for biotech, pharmaceutical, and venture capital clients working in drug discovery and development.
AgTechBiotechHealthtechLongevityWellness & FitnessMallorca, ES
Fernando BarreraDr. Rafel Prohens
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures
Devicare sells nutritional and health products, including supplements and monitoring devices for conditions such as kidney stones and urinary infections.
ConsumerHealthtechWellness & Fitness
Co-investorsCapital CellEmesa Corporación EmpresarialShip2BEuropean Investment Fund
Novel in vitro diagnostic biomarker for the early detection of cardiac ischemia.
InBioMotion offers a biomarker test that analyzes MAF gene levels to assess prognosis and guide personalized bisphosphonate treatment in early breast cancer patients.
BiotechDigital HealthMedical Devices
BoardProf Rob E. Coleman(Chairman)
Co-investorsYsios CapitalAlta Life SciencesAsabys Partners
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture FundYsios Capital+2 more
Nuubo offers a wireless, non-invasive cardiac monitoring technology (aECG) based on textile electrodes for medium- and long-term remote heart monitoring.
Digital HealthHardwareMedical Devices
Co-investorsCapital CellFides Capital
CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease.
BiotechHealthtechMedical Devices
Joan Perello Bestard(Founder)inCris Calsadain
Co-investorsAndera PartnersInvivo Capital PartnersYsios Capital
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundRoche Venture FundSanofi VenturesYsios CapitalAsabys PartnersNew Enterprise Associates (NEA)+3 more
Tolerance is a compliance platform that runs continuous automated checks against the NIST 800-171 standard and collects assessor-ready evidence for teams handling Controlled Unclassified Information (CUI).
CybersecurityGovTechSaaS
Co-investorsDorm RoomAmadeus Capital PartnersBen Franklin Technology PartnersBioAdvanceColumbus Venture PartnersEast Innovate+4 more
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.
BiotechDeep TechLongevityPhiladelphia, US
Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsBen Franklin Technology PartnersBioAdvanceColumbus Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
6a341b14a0269d64dd34ca59 verifiedMinoryxMosaic BiomedicalsNorthern Biologicsplay acWooptix
Portfolio news
latest coverage across their companies
Tolerance · medscape.com · Aug 10, 2026
Tolerance Bio · intelligence360.news · Jul 28, 2026
NRG Therapeutics · cen.acs.org · Sep 8, 2025
Frequently asked questions
- How many investments has Criteria Bio Ventures made?
- Criteria Bio Ventures has 22 tracked investments, including 3 dated in the last 24 months.
- What stage does Criteria Bio Ventures invest at?
- Criteria Bio Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Criteria Bio Ventures focus on?
- Criteria Bio Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Criteria Bio Ventures located?
- Criteria Bio Ventures is headquartered in Barcelona, ES.
- Does Criteria Bio Ventures lead rounds?
- Yes, Criteria Bio Ventures leads investment rounds.
- Who does Criteria Bio Ventures co-invest with?
- Criteria Bio Ventures most often shares deals with Ysios Capital, Fund+, Invivo Capital Partners, among 26 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.